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Receptor orphans find a family
A family of ligands has been identified for the largest group of receptor
protein-tyrosine kinases - the hitherto 'orphan' EPH receptor subfamily -
and the functions of these receptors and ligands are starting to be elucidated.
A characteristic feature of multicellular organisms is that
cells communicate with each other to coordinate their
activities. This communication is mediated by cell-
surface receptors and their ligands. The known receptors
fall into several distinct types, each with a characteristic
mechanism of transducing an extracellular signal into an
intracellular one. One of these major receptor types is the
receptor protein-tyrosine kinase type - these receptors
have intracellular kinase domains that are activated in
response to ligand stimulation, leading to autophos-
phorylation of tyrosine residues; the phosphorylated
tyrosines in turn bind to, and activate, a number of sig-
nalling molecules, turning on multiple signalling pathways
inside the cell.
The various receptor protein-tyrosine kinases have been
divided into subfamilies on the basis of their sequences.
The most recent classification [1] delineated 14 distinct
subfamilies of receptor protein-tyrosine kinases, includ-
ing the epidermal growth factor (EGF), platelet-derived
growth factor (PDGF), fibroblast growth factor (FGF)
and insulin receptors. The largest group is the 'EPH'
subfamily, which until recently were ligand-less, 'orphan'
receptors. Ligands for EPH-like receptors have, however,
now been identified, and constitute a rapidly expanding
family of glycosylphosphatidylinositol (GPI)-linked or
transmembrane molecules. Elucidation of the functions
of these receptor-ligand systems is just beginning, but it
seems likely that they play a number of important roles,
particularly in the development of the nervous system.
The EPH receptor subfamily
EPH subfamily receptors are characterized by an extra-
cellular region that includes an immunoglobulin-like
domain, a cysteine-rich sequence that is not related to
those in EGF or insulin receptors, and two fibronectin
type III repeats. There are 20 cysteines in the extracellu-
lar region that are conserved among all the subfamily
members. The cytoplasmic region contains a single tyro-
sine kinase domain and a non-catalytic tail of about 100
amino acids [1]. The prototypical member of this family,
EPH, was identified in a human genomic DNA library
during a search for gene sequences homologous to the
tyrosine kinase domain of the viral oncogene v-fps [2].
Subsequently, several members of this family have been
identified from various vertebrate species, including
humans, mouse, rat, Xenopus [3] and zebrafish [4]. To
date, 13 distinct members of this family have been
Fig. 1. Ligands for EPH subfamily recep-
tors. The ligand gene names were kindly
provided by Doug Cerretti, and have
been approved by the mouse and
human gene nomenclature committees.
The topologies of the two types of
ligand - GPI-linked (yellow shading)
and transmembrane (orange shading) -
are shown below the table listing the
known ligands.
© Current Biology 1995, Vol 5 No 9
CELL SIGNALLING
986
DISPATCH 987
discovered, comprising nearly a quarter of all known
receptor protein-tyrosine kinases.
Expression of EPH subfamily receptors
Initial clues to the likely functions of proteins discovered
on the basis of their gene sequences can come from
knowledge of where they are expressed. Several members
of the EPH subfamily are predominantly expressed in the
adult brain. These include Elk, Eek, Cek4, Cek5, Sek,
Ehk-1 and Ehk-2. Other members, however, such as
EPH, ECK, HTK, Cek9 and CeklO, have a broader
tissue distribution. The tissue distributions of many of
the EPH-like receptors have recently been reviewed by
Tuzi and Gullick [5]; three EPH-like receptors not
described in that review are Mdkl/Ehk-3/HEK11 [6-8],
Ehk-2 [9] and HTK/Myk-1 [10,11].
Mdkl/Ehk-3/HEK11 is expressed widely in the
embryonic brain as well as in a variety of other tissues,
including kidney, lung, heart and liver. In the adult, the
expression is diminished and more restricted to the brain,
testes and spleen [6-8]. Ehk-2 is almost exclusively
expressed in the brain, both in the embryo and in the
adult [9]. HTK is widely expressed in the embryo as well
as the adult; it is found in fetal heart, lung, liver, kidney
and brain. In the adult, HTK is expressed in placenta,
kidney, liver, lung, skeletal muscle, heart and pancreas,
with no detectable expression in brain. HTK mRNA is
also detected in primitive hematopoietic cells and in cell
lines derived from myeloid cells, but not in those derived
from lymphoid cells [101.
Ligands for EPH subfamily receptors
The first ligand to be identified for an EPH-like receptor
was B61, which was found to bind and activate ECK
[12,13]. Since then, several other ligands related to B61
have been discovered by expression cloning, using the
extracellular domains of EPH-like receptors expressed as
immunoglobulin or alkaline phosphatase fusion proteins
to detect ligand expression. Including B61, seven ligands
in this family have been identified to date (Fig. 1). Inter-
estingly, five of the ligands appear to be GPI-linked,
whereas the other two have transmembrane domains.
An alignment of the amino-acid sequences of the known
ligands for EPH-like receptors is shown in Figure 2. As
suggested by Kozlosky et al. [14], each ligand molecule
can be divided into four regions: a signal peptide, a
receptor-binding region, a spacer region and a hydro-
phobic region (Fig. 1). The only region of significant
identity over the whole family is the receptor-binding
region, in which there are four cysteines that are con-
served among all known ligands for EPH subfamily
receptors. A site for N-linked glycosylation, located near
the amino terminus of the mature peptide, is also highly
conserved, being present in all EPH-subfamily receptor
ligands except LERK-2/Elk-L/EFL-3. Htk L/LERK-5
and AL-1/RAGS, and LERK-3/Ehkl-L/EFL-2 and
ELF-1/Cek7 L, contain one and two additional puta-
tive N-linked glycosylation sites, respectively. The two
transmembrane ligands also show extensive sequence
identity in their spacer, hydrophobic transmembrane and
cytoplasmic regions.
Fig. 2. Alignment of the known
sequences of B61 -related ligands of EPH
subfamily receptors. All sequences
shown are human, except ELF-1/Cek7 L,
for which only the mouse sequence has
been published. The receptor-binding
domains of the GPI-linked ligands, and
the entire sequences of the transmem-
brane ligands, have been aligned, using
the MegAlign progam and visual inspec-
tion. The signal peptides are shown in
green, the receptor-binding domains in
black with regions of sequence similar-
ity highlighted in yellow, and the spacer
regions are red. The hydrophobic and
transmembrane regions are underlined;
residues conserved among all ligands
are boxed; and conserved cysteines are
indicated with a star. The spacer, trans-
membrane and cytoplasmic regions of
the two transmembrane ligands show
significant sequence identity to each
other and are shaded grey.
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Expression of EPH-like receptor ligands
The mRNA expression patterns of the EPH-like recep-
tor ligands are summarized in Table 1. Most of the data
come from northern-blot analyses of whole tissues. It is
apparent that, although many of the receptors are
restricted in expression to the brain in adults, the ligands
seem to have a more widespread expression. As the
expression patterns of the ligands are generalized and not
restricted to any preferred tissues, no obvious inference
can be drawn about their likely roles in vivo. None of the
ligand expression patterns exactly matches that of any
EPH-like receptor.
It is known, however, that the ligand B61 is an immediate-
early response gene in endothelial cells - its expression
is induced by proinflammatory factors such as tumor
necrosis factor-or (TNF-a), interleukin-1 (IL-1) and
lipopolysaccharide (LPS) [13]. The ligand LERK-2 has
similarly been shown to be induced by TNF-o in
endothelial cells [15]. Whether other ligands are also
induced by such proinflammatory factors has not yet
been determined.
Biological functions
It is clear from studies in which receptor-binding aff-
inities have been measured that any particular ligand in
this family has affinity for many (or all) of the EPH-like
receptors. Receptor activation, as measured by auto-
phosphorylation, varies depending upon how the assay is
performed. Experiments with artificially clustered, mem-
brane-bound or soluble ligands give differing results,
with the former two assay methods tending to show
greater activity and promiscuity ([16] and R.A.L.,
unpublished observations). Which in vitro assay is the
most relevant to function in vivo has yet to be deter-
mined. One would assume that both soluble and mem-
brane-bound ligands have physiological functions. The
determination of which receptor-ligand pairs are relevant
in vivo will therefore depend upon other data, such as
colocalization or genetic analyses.
The EPH gene has been shown to have transforming
potential when overexpressed in NIH3T3 cells [17]. It
has been found to be overexpressed, but not amplified, in
a few tumor cell lines [17]. ERK was similarly found to
be overexpressed in various tumors of epithelial origin,
especially gastric carcinomas [18]. This suggests that
overexpression of some of the EPH-like receptors may be
involved in oncogenic transformation, as has been seen in
the case of many other receptor protein-tyrosine kinases.
The activation of a chimeric molecule consisting of the
EGF extracellular domain and the Elk transmembrane
and cytoplasmic domains, however, did not lead to
proliferation of NIH3T3 cells [19]. At present, the data
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indicate that EPH subfamily receptors do not activate
proliferative pathways in cultured fibroblasts or endo-
thelial cells [19,20]. This may be one of the reasons why
identification of signalling pathways in the case of EPH
subfamily receptors has been slow compared to other,
mitogenic, receptor protein-tyrosine kinases.
As some of the ligands are expressed only when endo-
thelial cells are activated by proinflammatory factors, such
as TNF-ot, IL-1 and LPS, it was expected that the activa-
tion of EPH subfamily receptors would be involved in
certain aspects of inflammation. In this regard, B61 has
been shown to induce an angiogenic response in vivo
[20]. B61 also induces the migration of endothelial cells
[20], which may be mediated by phosphatidylinositol
3-kinase [21], an enzyme that has previously been impli-
cated in membrane ruffling and chemotactic responses to
ligand stimulation.
The in vivo expression patterns of EPH subfamily recep-
tors and their ligands would suggest that many of them
function in the nervous system. Many of the receptors,
including Nuk [22], have been predicted to play a role in
axonogenesis. The ligand AL-1/RAGS has recently been
shown to affect axonal fasciculation in one in vitro assay
[23], and to induce growth-cone collapse and have
axonal repellent activity in another [24]. Axonal guid-
ance and targetting may prove to be one of the major
functions of these receptors and their ligands. Elucidation
of the functions of these receptor-ligand systems has just
begun, but it seems likely that they will turn out to play
important roles in the development and maintenance of
many cell and tissue types.
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